Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

QuiaPEG och Net Zero Infrastucture take next step to a formal license agreement

QUIA PHARMA

The parties can now announce that the work regarding NZI's evaluation of QuiaPEG's intangible assets, as well as the drafting of a formal license agreement, is proceeding according to plan. Unless something unforeseen happens, the parties' ambition is to shortly agree on the final content and then also sign the license agreement. The potential transaction could potentially be completed around the end of March / beginning of April.

Given the progress in the process, the parties have also begun to prepare a prospectus, which is as a requirement from the British regulator FCA, in order for NZI to complete the transaction.

Mike Ellwood, Chairman of NZI, said, “During the process, we have been able to confirm our expectations of, and get an increasingly positive impression of, the potential of QuiaPEG's technology platform. For example, we see high potential in QuiaPEG's project QPG-1029 regarding a long-acting, pegylated version of liraglutide (Novo Nordisk's block buster pharmaceutical substance against obesity and diabetes). The dialogue with QuiaPEG is in good spirit and we hope to complete the process in the coming weeks.”

Marcus Bosson, CEO of QuiaPEG, said, “The process is proceeding according to plan, and we are very positive about continuing the work with NZI. Our ambition is to formalize a final agreement as soon as possible and that we can then take the next step in the commercialisation and development of QuiaPEG's assets.”

For more information, please contact:


Marcus Bosson
CEO
Tel: +46 (0) 70 693 12 53
E-mail: marcus.bosson@quiapeg.com 

About QuiaPEG Pharmaceuticals Holding AB


QuiaPEG Pharmaceuticals Holding AB is a drug development company which focuses on research, development and commercialization of its proprietary releasable drug-delivery platform Uni-Qleaver®. The company is listed on Nasdaq First North Growth Market (ticker: QUIA). For more information, please visit www.quiapeg.com.

Attachments


QuiaPEG och Net Zero Infrastucture take next step to a formal license agreement

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team